In this episode of Diabetic Foot Files, Dr. G explores how existing medications — from metformin and insulin to statins, fentanyl, sildenafil, doxycycline and nitric oxide donors — are being repurposed to help heal stubborn diabetic foot ulcers. We review the biology behind each drug, early clinical evidence, and why topical formulations may offer targeted benefits with minimal systemic exposure. Listeners will learn which agents show the strongest signals (topical insulin, topical metformin, topical statins), which remain promising but mixed (topical phenytoin), and how repurposed therapies fit as adjuncts to standard wound care rather than replacements. Practical takeaways include safety considerations, off-label use discussions, and the need for larger trials.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related